NCT01745055View on ClinicalTrials.gov

Co-Administration Of Methotrexate And CP-690,550

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Rheumatoid Arthritis
Interventions
DRUG

CP-690,550 (tofacitinib)

CP-690,550 30 mg q12h for 5 days

DRUG

Methotrexate (MTX)

individual dose of methotrexate (stably dosed)

Trial Locations (4)

32114

Pfizer Investigational Site, Daytona Beach

33025

Pfizer Investigational Site, Miramar

33301

Pfizer Investigational Site, Fort Lauderdale

75247

Pfizer Investigational Site, Dallas

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY